Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 14/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342568 | 1.00 | STAT3 (0.40) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL1345049 | 0.85 | GSK3B (0.42) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL1343287 | 0.83 | GSK3B (0.59) | GSK3B | |
| SCHEMBL1343226 | 0.83 | GSK3B (0.59) | GSK3B | |
| SCHEMBL5482130 | 0.74 | TOP2A (0.49) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL5473835 | 0.74 | TOP2A (0.49) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL3812517 | 0.73 | TOP2A (0.47) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL1345565 | 0.71 | PIM1 (0.35) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL1345771 | 0.70 | GSK3B (0.49) | STAT3TOP2ATOP2BGSK3BMEN1 | |
| SCHEMBL1344894 | 0.69 | STAT3 (0.49) | STAT3TOP2ATOP2BGSK3BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-2383271-A1 | Aminoquinolones as GSK-3 Inhibitors | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | STAT3 115/4885TOP2A 205/4885TOP2B 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.